| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 77,86 | 77,88 | 12:16 | |
| 77,85 | 77,88 | 12:16 |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 08:37 | Sanofi: Studie zeigt anhaltenden Schutz von Beyfortus gegen RSV | Sanofi (SNY) hat Ergebnisse einer neuen Studie zu seinem RSV-Präventionspräparat Beyfortus (Nirsevimab) vorgelegt. Wie der Pharmakonzern mitteilte, war ein universelles Immunisierungsprogramm bei Säuglingen... ► Artikel lesen | |
| 08:18 | Sanofi: Beyfortus Study Shows Benefit For Infants Beyond First RSV Season | PARIS (dpa-AFX) - Sanofi (SNY) said a universal respiratory syncytial virus immunization program using Beyfortus or nirsevimab was associated with a statistically significant reduction in RSV-related... ► Artikel lesen | |
| 07:10 | Sanofi: Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season | Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season
First study showing that infants immunized against RSV in their first season had fewer... ► Artikel lesen | |
| Fr | Belén Garijo soll Sanofi wieder in die Spur bringen | ||
| Fr | Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors |
